As we grow older, bone and joint diseases become more frequent and there are fewer effective weapons with which to combat them.
However, the discovery of bone morphogenetic proteins (BMP), which are naturally present in bones, represents a major advance.
In the early 1960s, Dr Marshall Urist, an orthopaedic surgeon, posed a fundamental question: what is the substance in bones that allows them to regenerate?
In the course of his research at the University of California (UCLA), Urist discovered a protein which, when combined with specific, mesenchymal stem cells, or MSC, activated those cells, transforming them into osteoblasts and chondrocytes,
This protein was named ‘Bone Morphogenetic Protein or BMP’.
His findings were published in the prestigious journal Science, under the title ‘Auto-induction of Bone’, a term coined to demonstrate the ability of a protein to join with certain stem cells to grow bone and cartilage tissue.
Advances in molecular and cell biology during the 1970s and 1980s revealed that it is not just one protein that is responsible but a group of 22 different proteins, 10 of which have a specific tropism for bone tissue. This family of proteins was named ‘Bone Morphogenetic Proteins’.
Naturally present in healthy bone and cartilage tissue, these proteins activate mesenchymal stem cells, turning them into either osteoblasts or chondrocytes which respectively stimulate the formation of bone and new cartilage.
A natural weapon for stimulating the formation and repair of bone and cartilage tissue
During the 1990s, the first commercial BMP complex was used by orthopaedic surgeons for bone and spinal healing.
It was only in 2007 that larger-scale studies enabled the development of Cyplexinol®, a genuine, all-natural, pharma-compliant ‘nutraceutical’.
In its mechanism of action, Cyplexinol® appears to be a stem cell activator. It comprises a protein-collagen complex which provides:
• natural bone morphogenetic proteins and
• key growth factors such as TGF-Beta (‘Transforming Growth Factor Beta’), responsible for developmental mechanisms and which thus ensure bone tissue regeneration.
Cyplexinol® naturally activates the growth of bones and cartilage and is thus functionally involved in bone and cartilage formation. In addition, it has natural immune-protective effects against inflammation through inhibition of interleukin 1 and 6, without the side-effects of NSAIDs.
Cyplexinol® is absorbed via specific receptors in the gastrointestinal tract which selectively distribute it to priority sites in the body. It has excellent bioavailability and efficacy in target tissues.
Cyplexinol® is obtained through a cold-process extraction method, certified by three different independent laboratories which test its biological activity. This is carried out in FDA-registered facilities in accordance with GMP.
Cyplexinol® has been used by thousands of health professionals, patients and consumers worldwide with considerable clinical success. It seems to be particularly effective at combatting incapacitating pain in the back, knees and hips. In addition, according to a recent study published in the April 2013 edition of Integrative Medicine, Cyplexinol® is statistically more effective than placebo at treating symptoms of arthritis in the hips and knees.
Other studies suggest Cyplexinol® may constitute an effective new therapy for treating osteoporosis.
Cyplexinol® can either be taken on its own, as outlined here or, for a more powerful and rapid synergistic effect, in combination with other osteo-articular nutritional supplements such as glucosamine, chondroitin, MSM, vitamin D3, magnesium or certain calcium salts.
A daily dose of around 150mg of Cyplexinol® is likely to produce benefits, though if necessary, this can be doubled or tripled without a problem.